SHINE Teams with Investor Relations Firm LifeSci Advisors

JANESVILLE, Wis., Dec. 11, 2017 (GLOBE NEWSWIRE) — SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it has joined forces with investor relations firm, LifeSci Advisors, LLC (“LifeSci”) to anchor its outreach to the broader investment community.  LifeSci is the leading international investor relations and corporate communications firm dedicated to the life sciences sector.

Johnson Outdoors Announces Cash Dividend

RACINE, Wis., Dec. 08, 2017 (GLOBE NEWSWIRE) — Johnson Outdoors Inc. (Nasdaq:JOUT), a global leader in innovative outdoor recreation equipment products, today announced approval by its Board of Directors of a quarterly cash dividend of $0.100 per Class A share and $0.0909 per Class B share.

Karmanos Cancer Institute’s 24th Annual Partners Night continues to drive the future of cancer research

DETROIT, Dec. 11, 2017 (GLOBE NEWSWIRE) — When dedicated community members, including those touched by cancer, come together to support cancer research at Karmanos, it’s another way of describing the Barbara Ann Karmanos Cancer Institute’s Partners Events. More than 300 champions supported this year’s exciting Partners Night at the M1 Concourse in Pontiac, Mich., on Oct. 28. The unique event generated nearly $500,000 to support the purchase of a Micro-PET/CT device, research technology critical for the evaluation of imaging approaches to assess cancer risk, detect cancer, help develop new drugs, guide treatment and monitor therapies.

Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 10, 2017 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today presented data from the randomized Phase 2 trial of its investigational intratumoral TLR4 agonist G100 plus low-dose radiation (G100 Monotherapy) with or without KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in follicular non-Hodgkin’s lymphoma (FL) patients. The G100 Monotherapy and pembrolizumab combination resulted in a 39% objective response rate (ORR), with a 57% ORR in those patients who expressed a potential predictive biomarker. These data were presented at the 59th American Society of Hematology (ASH) Annual meeting in Atlanta, Georgia on Sunday, December 10, 2017.

Washington County Virginia Sheriff’s Office One of the First U.S. Law Enforcement Agencies to Utilize the Busch VPAM-certified Ballistic Helmet from Armor Express

CENTRAL LAKE, Mich., Dec. 11, 2017 (GLOBE NEWSWIRE) — Central Lake Armor Express, Inc. (“Armor Express”), a leading manufacturer and distributor of high-performance body armor solutions, is excited to announce that the Washington County Virginia Sheriff’s Office (WCVSO) is one of the first U.S. law enforcement departments to employ Armor Express’ Busch AMP-1 TP helmet. Certified to the VPAM standard, the AMP-1 TP is currently being worn by the WCVSO’s Special Response Team (SRT) to provide the unit’s officers with critical, high-performance head protection.